Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GSK3389404 in Chronic Hepatitis B
NCT03020745Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
A Phase 2 trial of GSK3389404 in Chronic Hepatitis B (CHB), sponsored by GSK. Started Feb 2017; status: completed.
02
Drugs
GSK3389404
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03020745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020745.